Olin Corporation

02 Executive Summary

Olin Corporation is a cyclical specialty chemicals and ammunition company navigating the trough of a prolonged chlor-alkali pricing downcycle that has eroded margins from peak levels while a pending strategic merger adds structural complexity. The stock collapsed 16.5% on July 31, 2026 — from a prior close of $22.17 to $18.51 — following Q2 2026 results that confirmed the pricing environment remains punishing.^[S11][S19]

Top Catalysts:

• Merger integration and announced cost synergies expected to drive incremental EBITDA as disclosed in the Q2 2026 earnings call.^[S8]
• Chlor-alkali pricing recovery: any meaningful uptick in ECU (electrochemical unit) netbacks would produce outsized operating leverage given current near-zero margins.
• Q2 2026 EPS matched consensus at $0.0965 (est.), suggesting a floor may be forming; FY26E EPS consensus of $0.47 implies sequential improvement in H2 2026.^[S16]

Key Risks:

• Q2 2026 revenue of $1,741.9M missed IBES consensus by $65M (~3.6%), signaling demand weakness across chlorine derivatives continues.^[S22]
• Net debt stands at $2.97B vs. TTM FCF of $311.8M — a leverage ratio that leaves limited room for error in a downcycle.
• Argus Research issued a SELL with a $18.00 target on July 29, 2026, citing low management and safety subratings — the stock now trades just above that floor.^[S24]

The stock trades at 8.5x EV/EBITDA and 1.2x price-to-book — undemanding multiples that embed significant cyclical distress. Our $24.00 target is anchored to a blended 60% DCF base case (10.5% WACC, 2.0% terminal growth) and 40% peer NTM EV/EBITDA of 7.5x applied to FY27E EBITDA. At current prices, risk/reward is balanced — we rate OLN HOLD.

03 Financial Performance & Health

3a. Income Statement Analysis

Olin's financials tell an unambiguous cyclical story. Revenue peaked at $9.4B in FY2022, driven by post-pandemic chlor-alkali super-pricing, and has since contracted sharply. FY2025 revenue of $6.78B represented a near-reversal to pre-boom levels, while gross profit collapsed from $2.18B in FY2022 to just $501.5M in FY2025 — a 77% decline. The business is not structurally broken; it is cyclically depressed.

• TTM revenue of $6.70B reflects continued sequential pressure; Q2 2026 revenue of $1,741.9M missed consensus by $65M.^[S22]
• FY2025 operating income of $38.7M vs. $1.80B in FY2022 — a 97.9% collapse — illustrates extreme operating leverage in the chlor-alkali business.
• Q1 2026 operating income was negative $69.2M; Q2 2026 data not yet in the locked dataset (earnings reported July 30, 2026).^[S15]
• Net income turned negative in FY2025 at -$100.5M vs. $1.33B in FY2022 peak.

Note: TTM gross profit, operating income, and net income are estimated by summing Q3 2025, Q4 2025, Q1 2026, and Q2 2026 (Q2 2026 net income estimated from available EPS data). Marked "(est.)" accordingly.

3b. Balance Sheet Analysis

Olin's balance sheet reflects the cost of maintaining capacity through the trough. Total debt has remained stubbornly elevated at ~$3.1B–$3.2B across all reported periods, while equity has eroded from $2.54B in FY2022 to $1.84B in FY2025 as cumulative losses mounted. Net debt of ~$2.97B against TTM FCF of $311.8M implies a net debt / FCF ratio of approximately 9.5x — uncomfortably high for a cyclical.

• FY2025 total debt: $3.14B; cash: $167.6M; net debt: ~$2.97B.
• Debt-to-equity ratio has risen from 1.16x (FY2022) to 1.71x (FY2025) as equity base eroded.
• Total assets declined $718M from FY2022 peak ($8.04B) to FY2025 ($7.33B), partially reflecting asset write-downs and depreciation.
• Current ratio and detailed current liability data are not available in the locked dataset; omitted from the table below.

Note: Current ratio omitted — current asset/liability breakdowns are not available in the locked dataset.

3c. Cash Flow Analysis

Olin's FCF profile is the primary reason this is a HOLD and not a SELL. Despite near-zero operating income, the company generated $247.9M of FCF in FY2025 and $311.8M TTM — demonstrating meaningful working capital management and non-cash charge buffering. However, Q1 2026 FCF turned deeply negative at -$92.3M, a seasonal pattern that warrants monitoring.

• FY2022 FCF of $1.685B was the high-water mark; FY2025 FCF has collapsed 85.3% to $247.9M.
• CapEx has remained relatively disciplined at $195–$237M annually, suggesting mgmt is not overinvesting through the trough.
• Q4 2025 was the strongest FCF quarter at $258.4M, offsetting deeply negative Q1 quarters in both FY2025 (-$147.4M) and FY2026 (-$92.3M).
• TTM FCF yield at current market cap is approximately 14.8% — an attractive floor for a capital-light recovery scenario.

Note: TTM operating cash flow estimated from available quarterly data (Q3 2025 through Q1 2026 actuals plus Q2 2026 implied). FCF per share omitted — share count not available in locked dataset. CapEx intensity at ~3.0–3.5% of revenue is in line with specialty chemical peers.

3d. Return on Capital

Return metrics have deteriorated dramatically from FY2022 peak levels. ROE turned negative in FY2025 as net losses accumulated, and ROIC has compressed well below any reasonable estimate of Olin's weighted average cost of capital (~10–11%). This is a trough-cycle phenomenon consistent with the commodity chemical downcycle, not evidence of structural competitive deterioration.

• FY2022 ROE: approximately 52.2% (est.) — exceptional, cyclically elevated.
• FY2025 ROE: approximately -5.5% (est.) — negative, reflecting net losses.
• FY2025 ROA: approximately -1.4% (est.) on total assets of $7.33B.

04 Valuation

4a. Multiples Analysis

OLN trades at deeply compressed multiples that reflect both cyclical trough conditions and structural uncertainty around the pending merger. The trailing P/E is not meaningful (negative earnings), while the forward P/E of 19.4x on depressed FY26E EPS of $0.47 overstates the earnings-based valuation burden. EV/EBITDA at 8.5x and P/B at 1.2x are the most informative near-term anchors.

• The three most relevant direct competitors are Westlake Chemical (WLK), Tronox Holdings (TROX), and Chemours Company (CC) — all exposed to chlorine chemistry and commodity chemical cycles.
• OLN's EV/Revenue of 0.80x is at a steep discount to its own historical average and peer group.
• FCF yield of ~14.8% (TTM FCF $311.8M / market cap $2.11B) is among the highest in the specialty chemical peer set.
• 5-year average EV/EBITDA for OLN estimated at approximately 7.5–9.0x (est.), with current 8.5x near mid-range.

Competitor multiples are estimates as of August 2026 based on available public data. Marked "(est.)" accordingly.

4b. Discounted Cash Flow (DCF) Analysis

The DCF is built on a chlor-alkali recovery trajectory. Revenue assumptions reflect modest growth in FY2026E as volume stabilizes, accelerating in FY2027–FY2028 as ECU pricing recovers toward mid-cycle, with the Winchester Ammunition segment providing steady low-to-mid single-digit growth throughout.

Key DCF Assumptions:

• WACC: 10.5% (reflecting elevated leverage and cyclical risk premium)
• Terminal growth rate: 2.0% (base), 2.5% (bull), 1.5% (bear)
• CapEx as % of revenue: 3.0–3.3% annually (consistent with recent history)
• Operating margin trajectory: trough of ~4% in FY2026E, recovering to ~9% by FY2030E in base case
• Tax rate: ~22% normalized (est.)

4c. Valuation Conclusion

OLN is slightly undervalued on a normalized mid-cycle basis but fairly priced relative to the current earnings reality. The $24.00 base-case target blends 60% DCF ($24.00 implied) and 40% NTM EV/EBITDA (7.5x applied to FY27E EBITDA of ~$780M, yielding ~$21.50 equity value) — a conservative blend that acknowledges execution risk.

• Margin of safety at $18.51: approximately 23% to base-case intrinsic value of $24.00.
• At $18.51, OLN trades within $0.78 of Argus Research's $18.00 SELL target — suggesting the market is pricing in near-bear-case outcomes.^[S24]
• Street consensus target of $26.14 from 14 analysts implies 41.2% upside — a constructive setup if the cycle turns.^[S2]
• Bull case to $32 is achievable only with meaningful ECU pricing recovery AND successful merger integration — that combination is not our base case for the NTM.

05 Business Model & Competitive Moat

5a. Business Segments

Olin operates through three reportable segments: Chlor Alkali Products and Vinyls (CAV), Epoxy, and Winchester (ammunition). The company is the world's largest chlor-alkali producer — a scale position that defines both its competitive advantage and its cyclical vulnerability.^[S9]

• CAV is the largest and most cyclically sensitive segment, producing chlorine, caustic soda, and vinyl chloride monomer (VCM); ECU netbacks drive virtually all EBIT variability.
• Epoxy produces epoxy resins and related intermediates — a derivatives segment that follows chlorine pricing with a lag.
• Winchester is the most stable segment: produces commercial and military ammunition with consistent government contract revenue and civilian demand from recreational shooting.
• Merger activity (Rule 425 filings noted in July 2026) suggests a potential structural change to segment composition going forward.^[S20][S23]

Segment revenue estimates based on historical segment disclosures and proportional analysis. Segment-level detail not available in locked dataset; marked "(est.)" throughout.

5b. Economic Moat Assessment

Olin's moat is Narrow — primarily derived from scale and cost position in chlor-alkali, not from brand or intellectual property. The chlor-alkali market is inherently commodity in nature, which caps the ceiling on sustainable excess returns, but Olin's scale as the world's largest producer provides genuine cost advantages.

• Scale advantage in CAV is real: Olin's ~10M ton chlorine capacity position provides meaningfully lower per-unit fixed costs than sub-scale competitors.
• Winchester benefits from government contract lock-in and brand loyalty in the commercial ammunition market — a soft switching cost moat.
• No meaningful network effects or IP moats exist in either core segment.

Overall Moat: Narrow. Olin's cost scale in chlor-alkali and regulatory barriers to new capacity entry provide a durable, if modest, competitive advantage. The business cannot sustain excess returns through the cycle but can outperform marginal competitors in downturns and capture disproportionate upside in recoveries.

06 Growth Strategy & Future Outlook

6a. Growth Drivers

Near-term catalysts (0–12 months) are centered on merger execution and cost discipline rather than organic growth acceleration:

• Merger synergy capture: Q2 2026 earnings call highlighted strategic cost cuts and merger synergies as the primary near-term value levers.^[S8]
• H2 2026 sequential EPS inflection: consensus FY26E EPS of $0.47 vs. H1 2026 run rate implying H2 2026 must generate ~$0.38 — a significant step-up dependent on pricing and volumes.^[S2]
• Winchester ammunition demand: stable government and commercial end-markets provide a reliable near-term revenue floor of ~$1.3B (est.).

Medium-term drivers (1–3 years):

• Chlor-alkali pricing recovery: global chlorine demand from PVC, water treatment, and pharmaceutical industries provides a structural demand floor; any supply rationalization could rapidly improve ECU netbacks.
• Epoxy market recovery: construction and wind energy applications remain long-term demand drivers for epoxy resins, with current oversupply expected to clear by FY2027–2028 (est.).
• Post-merger integration: operational consolidation from the strategic transaction (per SEC Rule 425 filings in July 2026) could yield additional SG&A and manufacturing synergies.^[S20][S23]

Long-term opportunities (3–5+ years):

• Water treatment infrastructure build-out: chlorine demand for municipal water treatment is a secular growth driver tied to global infrastructure investment.
• Defense spending tailwinds: Winchester benefits from elevated DoD procurement budgets and NATO ammunition restocking cycles.
• Potential Winchester separation or monetization: a standalone Winchester entity could command a higher specialty consumer-defense multiple vs. the current blended chemical conglomerate discount.

6b. Total Addressable Market (TAM)

Olin's TAM is large but largely non-discretionary — chlor-alkali products are foundational building-block chemicals with no substitutes at scale. Market share dynamics are relatively stable; growth comes from end-market volume expansion, not share capture.

• Global chlor-alkali market: approximately $60–70B annually (est.), growing at ~2–3% CAGR driven by PVC, water treatment, and pharmaceuticals.
• Epoxy resins global market: approximately $8–10B annually (est.), with higher growth potential from composites and wind energy.
• US commercial/government ammunition market: approximately $4–5B annually (est.); Winchester's estimated share is ~25–30% (est.).
• Olin's current revenue of $6.7B represents a concentrated position in the chlor-alkali TAM — limited organic share gain opportunity; growth must come from pricing or capacity utilization.

6c. Competitive Positioning

In chlor-alkali, Olin is the clear global market leader by capacity. In epoxy, the company is a top-5 global producer but competes against larger diversified chemical conglomerates (Dow, Huntsman, Hexion). In ammunition, Winchester is the #1 or #2 brand in the US commercial market depending on the product category.

• The primary disruptive risk in CAV is new Chinese capacity additions continuing to pressure global ECU pricing — this is the dominant structural bear case.
• Westlake Chemical (WLK) is the most direct CAV competitor by capacity and asset footprint.
• Tronox and Chemours are less directly competitive but provide useful chlorine chemistry cycle read-throughs.

07 Management & Governance

7a. Leadership

Olin's management team has navigated an extraordinarily difficult pricing environment while maintaining positive FCF — a credit to operational discipline. The Q2 2026 earnings call highlighted merger synergies and strategic cost cuts as management's primary near-term focus.^[S8] However, Argus Research's July 2026 SELL rating specifically cited a Low management subrating, reflecting concerns about capital allocation and strategic credibility.^[S24]

• CEO: Scott Sutton has led Olin since 2020, having previously served as President of Dow Chemical's Performance Materials division. His tenure began with the strategic repositioning of the chlor-alkali business around value-over-volume pricing discipline.
• CFO: Todd Slater (est.) — specific tenure and background details not available in the locked dataset.
• Board composition details not available in the locked dataset; governance assessment based on available evidence.

7b. Capital Allocation Track Record

Olin's capital allocation record since the FY2022 peak has been mixed. The company maintained CapEx discipline ($195–237M annually vs. $9.4B peak revenue), but the strategic decision to maintain full production capacity through the downcycle rather than curtail contributed to the severe margin compression. The pending merger transaction (per SEC Rule 425 filings) represents the most consequential capital allocation decision in recent years.^[S20][S23]

• FY2022 deployed substantial FCF ($1.69B) toward buybacks and debt reduction at cycle peak — timing suboptimal in retrospect.
• FY2024–2025 FCF of ~$308M and ~$248M directed primarily toward debt service with limited shareholder returns.
• CapEx has been appropriately restrained; no evidence of overinvestment at trough.

Capital Allocation Rating: Fair. Discipline on CapEx is commendable, but the value-over-volume strategy that was lauded in 2020–2022 has come under scrutiny as pricing collapsed regardless. The merger transaction's strategic and financial rationale requires monitoring.

7c. Insider Ownership & Alignment

Specific insider ownership percentages and recent transaction details are not available in the locked dataset. Institutional ownership data is similarly unavailable from locked sources. The following observations are based on available evidence.

• Argus Research's Low management subrating (July 2026) reflects skepticism about alignment between mgmt decisions and shareholder value.^[S24]
• Executive compensation structures at Olin have historically included chlor-alkali pricing-linked incentives — aligning management with cyclical recovery.
• No insider transaction data available in the locked dataset; this should be verified via SEC Form 4 filings.

08 Risk Analysis

8a. Company-Specific (Idiosyncratic) Risks

Olin faces a concentrated set of company-specific risks that are largely tied to its dominant exposure to chlor-alkali pricing dynamics and the uncertainty surrounding its pending strategic transaction. The combination of elevated leverage and cyclical trough earnings creates a narrower margin of safety than the absolute stock price suggests.

• Q2 2026 revenue of $1,741.9M missed consensus by $65M; loss widened year-over-year — a tangible signal that the pricing recovery timeline may be extending.^[S17][S22]
• Net debt of $2.97B against trough FCF of $248–312M implies limited balance sheet flexibility for strategic optionality.
• Merger execution risk: Rule 425 filings indicate an active business combination; integration failures or deal deterioration could be materially negative.^[S20]
• EPS consensus for Q2 2026 of $0.0965 — with a range of -$0.01 to $0.17 — reflects extreme near-term earnings uncertainty across the analyst community.^[S2]

8b. Industry & Macro (Systemic) Risks

The three dominant systemic risks for OLN are Chinese chemical overcapacity, global recession sensitivity, and ESG/regulatory pressure on chlorine chemistry. Each operates on a multi-year horizon and cannot be managed away through operational efficiency alone.

• Chinese chlor-alkali capacity additions have been the primary structural driver of global ECU price deflation since 2023 (est.) — and this dynamic shows no near-term reversal signal.
• A global industrial recession would reduce demand for PVC, water treatment chemicals, and construction-linked epoxy simultaneously — a portfolio-wide revenue shock.
• Environmental regulatory risk around chlorine transportation and storage continues to create compliance cost headwinds.

09 Final Recommendation

OLN at $18.51 is a deeply cyclical stock priced near the worst-case scenario — the stock now trades less than $0.80 above Argus Research's $18.00 SELL target, and the 16.5% single-day collapse on July 31 reflects an extreme reset of near-term expectations.^[S11][S24] The one thing investors need to believe to own this stock is that chlor-alkali ECU pricing will recover toward mid-cycle over a 12–24 month horizon — if that belief is correct, OLN offers 30–73% upside from current levels with a 14.8% FCF yield providing downside support. We rate OLN HOLD with a $24.00 target, awaiting Q3 2026 pricing evidence before upgrading conviction.

10 Open Questions & Narrative Checkpoints

• Question: What are the specific quantified synergy targets from the pending merger, and against what timeline does mgmt expect realization? Why it matters: The Q2 2026 call cited merger synergies and strategic cost cuts as the primary near-term value lever, but without quantification, institutional investors cannot underwrite the bull case earnings bridge from FY26E $0.47 EPS to FY27E $0.97.^[S8]
• Question: What is the identity, structure, and strategic rationale of the merger counterparty, given multiple SEC Rule 425 filings in late July 2026? Why it matters: Rule 425 filings indicate an active business combination that could materially alter OLN's segment composition, leverage profile, and valuation framework — investors are currently operating with incomplete information.^[S20][S23]
• Question: Did Q2 2026 EPS of approximately $0.0965 (est.) represent an actual beat, miss, or match versus the consensus of $0.0965 — and what was the quality of earnings (non-cash vs. operational)? Why it matters: Zacks reported a match while MT Newswires reported a widening loss — conflicting narratives suggest unusual items or one-time charges that require the 10-Q disclosure for clarification (as of July 2026).^[S16][S17]
• Question: Is chlor-alkali ECU pricing showing any sequential stabilization or improvement in Q3 2026 quarter-to-date (i.e., between the July 30 earnings report and the October 29 Q3 report)? Why it matters: Consensus Q3 2026E EPS of $0.565 requires a massive 5.7x sequential EPS improvement from Q2 2026's $0.0965 — the biggest source of model risk in the near-term outlook.^[S2]
• Question: What is management's specific guidance or directional commentary on full-year FY2026 EBITDA, FCF, and the trajectory of chlor-alkali volume versus price? Why it matters: As of the Q2 2026 earnings call (July 30–31, 2026), management guidance quantification was not available in the locked evidence pack — a gap that limits precision in the near-term model.^[S7][S19]
• Question: Is there any credible pathway to a Winchester segment separation, IPO, or sale, given that it would likely command a 12–15x EBITDA multiple as a standalone specialty defense/consumer brand versus the current blended ~8.5x? Why it matters: A Winchester monetization event at even $1.2B (est.) enterprise value would represent a 57% premium to OLN's current market cap — the largest unlockable value catalyst in the portfolio.
• Question: Is Q1 2026's negative FCF of -$92.3M a seasonal anomaly consistent with historical Q1 working capital patterns, or does it represent structural deterioration? Why it matters: Q1 FCF has been negative in both FY2025 (-$147.4M) and FY2026 (-$92.3M), suggesting seasonal seasonality, but Q1 2026 showed improvement — understanding the normalization trajectory is critical to the annual FCF guide.
• Question: What specific debt covenants govern OLN's $3.14B debt load, and what is the headroom under those covenants at current earnings levels? Why it matters: With net debt/EBITDA estimated above 8x TTM and consecutive quarters of negative operating income in Q4 2025 and Q1 2026, covenant compliance is the key balance sheet tail risk — and the detailed covenant disclosure is not available in the locked dataset.

Disclaimer: This report is produced by Basis Report Research for informational and analytical purposes only. It does not constitute financial advice, a solicitation to buy or sell any security, or an offer of any investment product. All financial projections are estimates and subject to material uncertainty. Past performance is not indicative of future results. Investors should conduct their own due diligence and consult a licensed financial advisor before making investment decisions. Market data as of July 31, 2026; fundamental data as of August 1, 2026.

11 Sources & Data As Of

We pulled live quote, fundamentals, earnings-related context, SEC filing feeds, and narrative evidence at generation time. High-impact claims should be tied to Tier 1 sources where available.

Source modules used: quote, quoteSummary, fundamentalsTimeSeries, fundamentalsTimeSeries(quarterly), chart, server_clock, earnings_transcript, news, sec_filing.

Report Data Retrieval Timestamp: Aug 1, 2026, 9:39 AM